Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

First Amendment Challenge To DTC Rule Unlikely From Industry; For Now, It Is 'Comply With Context'

Executive Summary

DTC rule is a good fight to lose: it is a high-profile response to pricing, but will have a low impact – and is certainly a less painful solution than many of the alternatives.

You may also be interested in...



DTC Ad Final Rule Means Reliance On PhRMA Program Risks Enforcement Action – Azar

Nevertheless, the Pharmaceutical Research and Manufacturers of America announces enhancement of its drug pricing disclosures voluntary program, a Medicines Assistance Tool website that links to individual company sites, in response to the US rule.

Trump Administration's Rx-Price-Disclosure Reg Sets Up Legal Fight With PhRMA

From kinds of ads targeted to agency that's issuing the reg, policy seems designed to withstand a court challenge.

NDAs, BLAs To Start Getting KASA Quality Risk Assessments After Successful Pilot With ANDAs

Internal review system reduces US FDA’s administrative work for OPQ risk assessments; agency’s standards will not change, and sponsors will not need to modify applications. Advisory committee endorses expansion, which will roll out to different application types over several years.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS125370

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel